Tempus AI, Inc. (TEM) Earnings Yield: N/A
The earnings yield for Tempus AI, Inc. (TEM) is N/A as of Friday, June 12, 2026.
TEM Earnings Yield Chart
TEM Average Earnings Yield Chart
TEM Earnings Yield Metrics
EARNINGS YIELD
N/A
EARNINGS YIELD AVG TTM
-7.64%
EARNINGS YIELD AVG 3Y
-5.74%
EARNINGS YIELD AVG 5Y
-4.97%
EARNINGS YIELD AVG 10Y
-4.52%
EARNINGS YIELD AVG 15Y
-4.52%
EARNINGS YIELD AVG 20Y
-4.52%
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
TEM Competitors' Earnings Yield
| NAME | MARKET CAP | EARNINGS YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tempus AI, Inc. (TEM) | $8.65B | N/A | -7.64% | -5.74% | -4.97% |
| Charles River Laboratories International, Inc. (CRL) | $8.94B | N/A | 3.32% | 3.92% | 3.29% |
| Bio-Rad Laboratories, Inc. (BIO) | $7.92B | 2.06% | 5.85% | 5.85% | 16.96% |
| Baxter International Inc. (BAX) | $10.58B | N/A | 10.19% | 8.29% | 5.38% |
| Hims & Hers Health, Inc. (HIMS) | $6.19B | N/A | 1.75% | 1.50% | 1.50% |
| Align Technology, Inc. (ALGN) | $12.27B | 3.48% | 3.51% | 2.67% | 2.48% |
| Solventum Corporation (SOLV) | $13.72B | 10.31% | 8.09% | 8.15% | 8.15% |
| Hologic, Inc. (HOLX) | $16.97B | 3.16% | 3.63% | 3.48% | 5.61% |
| 23andMe Holding Co. (ME) | $15.31M | N/A | -866.48% | -444.06% | -297.83% |
| Moderna, Inc. (MRNA) | $18.71B | N/A | 10.37% | 11.47% | 11.47% |
Earnings Yield vs P/E Ratio
Earnings Yield
N/A
EPS ÷ Price
P/E Ratio
N/A
Price ÷ EPS
Formula: Earnings Yield = (EPS / Price) × 100
Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.
How earnings yield is used:
- It expresses earnings relative to share price as a percentage
- It can be compared with FCF yield and dividend yield
- It can be compared with bond yields because both are percentages
- It is mathematically the inverse of the P/E ratio
Tempus AI, Inc. Earnings Yield Formula & Definition
Earnings Yield = EPS (TTM) / Share Price
Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Tempus AI, Inc. Earnings Yield FAQ
- What is the earnings yield for Tempus AI, Inc. (TEM)?
- The earnings yield for TEM stock is N/A.
- What is the TTM average earnings yield for Tempus AI, Inc. (TEM)?
- The TTM average earnings yield for TEM stock is -7.64%.
- What is the 3Y average earnings yield for Tempus AI, Inc. (TEM)?
- The 3Y average earnings yield for TEM stock is -5.74%.
- What is the 5Y average earnings yield for Tempus AI, Inc. (TEM)?
- The 5Y average earnings yield for TEM stock is -4.97%.
- What is the 10Y average earnings yield for Tempus AI, Inc. (TEM)?
- The 10Y average earnings yield for TEM stock is -4.52%.
- What is the 15Y average earnings yield for Tempus AI, Inc. (TEM)?
- The 15Y average earnings yield for TEM stock is -4.52%.
- What is the 20Y average earnings yield for Tempus AI, Inc. (TEM)?
- The 20Y average earnings yield for TEM stock is -4.52%.
Tempus AI, Inc. Earnings Yield History
| DATE | EARNINGS YIELD |
|---|---|
| 2025-12-31 | -2.38% |
| 2024-12-31 | -12.90% |
| 2023-12-31 | -3.45% |
| 2022-12-31 | -4.24% |
| 2021-12-31 | -3.79% |
| 2020-12-31 | -3.07% |
| 2019-12-31 | -1.78% |
Related Metrics
About Tempus AI, Inc.
Tempus AI, Inc. functions as a pioneering health technology enterprise. It specializes in delivering advanced diagnostic services, including cutting-edge genomic sequencing, PCR analysis, molecular genotyping, and various other anatomical and molecular pathology assessments. These vital services are provided to a diverse clientele, including medical practitioners, pharmaceutical companies, biotechnology innovators, scientific researchers, and other collaborating entities. The company offers "Insights," a licensed repository of de-identified clinical, molecular, and imaging data, complemented by a comprehensive suite of analytical and cloud-based computing services, primarily aimed at pharmaceutical and biotechnology firms. Additionally, its "Trials" program facilitates clinical trial matching services specifically for pharmaceutical companies. Tempus AI also manages several other platforms: "Next"; "Algos," a collection of algorithm-driven tests focused on oncology; "Hub," a versatile desktop and mobile application for ordering, managing, and receiving test results for patients; and "Lens," a dedicated portal enabling researchers and scientists to discover, access, and analyze the extensive Tempus dataset. Further demonstrating its commitment to innovation, Tempus AI has formed strategic alliances with AstraZeneca and Pathos AI, Inc. for the co-development of oncological therapeutic initiatives. Established in 2015, the company was initially known as Tempus Labs, Inc. before officially rebranding to Tempus AI, Inc. in January 2023. Its operations are based out of Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Eric Lefkofsky